Phaseline

Targets › C3

C3 (Complement C3): drug programs, companies and trials

9 programs from 6 companies in 14 trials: 5 Phase 2, 4 Phase 3, 4 Phase 1, 1 Phase 4; Genitourinary, Ophthalmology, Other; next expected readout Dec 2026.

Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system..; FUNCTION: [Complement C3b]: Non-enzymatic component of C5 convertase. Generated following cleavage by C3 convertase, it covalently attaches to the surface of…. (UniProt, P01024)

Open in Phaseline: the race on C3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Swedish Orphan BiovitrumPegcetacoplan
Complement C3 inhibitor
C3Phase 4C3 Glomerulopathy (C3G)Dec 2031
AnnexonTanruprubart (ANX005)
C3 complement inhibitor
C3Phase 3Guillain-Barre SyndromeMay 2027
Apellis PharmaceuticalsPegcetacoplan
Complement C3 inhibitor
C3Phase 3C3G; Paroxysmal Nocturnal Hemoglobinuria (PNH); Fallopian Tube Carcinosarcoma; Metastatic Pancreatic Ductal AdenocarcinomaJul 2027
AnnexonVonaprument (ANX007)
Complement 3 (C3) inhibitor
C3Phase 3Geographic AtrophyJul 2027
Kodiak SciencesTarcocimab tedromer
Monoclonal antibody against complement factor C3
C3Phase 3Wet Age-related Macular DegenerationAug 2027
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing)RG002C0106
siRNA targeting complement C3 to silence the gene and inhibit C3 protein expression
C3Phase 2IgA Nephropathy (IgAN); Safety Issues; Renal ImpairmentsDec 2026
Apellis PharmaceuticalsAPL-3007
Complement C3 inhibitor
C3Phase 2Geographic Atrophy Secondary to Age-related Macular DegenerationJun 2027
Apellis PharmaceuticalsAPL2
Complement C3 inhibitor
C3Phase 2FSGSOct 2029
Shenyang Sunshine PharmaceuticalSSS55 injection
complement C3b inhibitor
C3Phase 1Safety IssuesDec 2026

Conditions

Safety Issues (2) FSGS (1) C3G (1) Paroxysmal Nocturnal Hemoglobinuria (PNH) (1) Fallopian Tube Carcinosarcoma (1) Metastatic Pancreatic Ductal Adenocarcinoma (1) Wet Age-related Macular Degeneration (1) IgA Nephropathy (IgAN) (1) Renal Impairments (1) Geographic Atrophy (1) Guillain-Barre Syndrome (1) Geographic Atrophy Secondary to Age-related Macular Degeneration (1)

Modalities

small molecule (7), mixed (1), antibody (1)

Companies

Apellis Pharmaceuticals (3) Annexon (2) Kodiak Sciences (1) Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) (1) Shenyang Sunshine Pharmaceutical (1) Swedish Orphan Biovitrum (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.